RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on October 29, 2013 have approved change of financial year of the Company from January-December to April-March effective April 01, 2014. In view of this, the current financial year will be for a period of 15 months i.e. January, 2013 to March, 2014.

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 23, 2012 has decided to : (1) Re-appoint Mr. Arun Sawhney as CEO & Managing Director of the Company for a period of 5 years effective January 01, 2012, subject to requisite approvals.

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors at its meeting held on July 24, 2009, the Board has approved for seeking consent of the Shareholders through postal ballot for appointment and payment of remuneration to - (I) Mr. Atul Sobti as CEO & Managing Director of the Company for a period of three years effective May 24, 2009 and (II) Mr. Malvinder Mohan Singh as Chairman, CEO & Managing Director for the period from December 19,2008 to May 24, 2009 ( the date he stepped down from the said positions).

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors of the Company in its meeting held on October 31, 2008 took note of the resignation of Mr. Nimesh N. Kampani from the directorship of the Company w.e.f. November 3, 2008.

Ranbaxy Laboratories Ltd has informed the Exchange regarding Outcome of Board Meeting held on June 11, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Outcomebm_11062008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors at its meeting held on January 17, 2008 inter-alia has approved the following: (1) Appointment of Dr.Brian W.Tempest as a Non-Executive Director of the Company effective January 17, 2008. Dr. Brian W. Tempest had retired from the services of the Company as Chief Mentor and Executive Vice Chairman of the Board of Directors of the Company on December 31, 2007 on completion of his term. (2) Consideration of Scheme of Arrangement for Demerger of New Drug Discovery Research Unit of the Company into a separate entity has

Ranbaxy Laboratories Ltd has informed the Exchange that the BODs at its meeting held on September 09, 2005, has approved the following subject to requisite approvals: 1) Listing of the Securities of the Company at a Stock Exchange in USA either through conversion of existing Global Depositary Receipts (GDRs) into American Depositary Receipts (ADRs) and/or through issuance of fresh security/instrument. 2) Raising of resources through appropriate securities such as FCCBs and/or GDRs and/or ADRs and/or any other appropriate security/instrument upto USD 1.5 Billion equivalent from time to time. 3